Acceleron Pharma is focused on developing therapeutics for metabolic and musculoskeletal diseases affecting millions of people. The company was founded with an interesting intellectual property portfolio and a deep knowledge of the largely untapped TGF-beta superfamily. The company has multiple programs in development. Furthermore, the company has created a proprietary discovery and development platform to deepen its pipeline and advance product candidates rapidly and efficiently.

Visit the site

Acutus is working to develop a novel electro-anatomical mapping catheter for atrial fibrillation ablation procedures.  The Acutus system integrates ultrasound technology and a proprietary dipole density mapping technology to generate a three dimensional image of the left atrium over which the electric activity of the chamber can be precisely displayed in real time.

Visit the site

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.

Visit the site

Aerocrine is a medical technology company focused on improving the treatment of patients with inflamed airways. Measuring airways inflammation helps doctors to diagnose, monitor and optimise therapy for people with inflammatory airway diseases. The founders of Aerocrine emerged from the highly prestigious Karolinska Institute in Sweden where they were the first to identify nitric oxide (NO) as a marker of inflammation. Aerocrine has taken this significant discovery from laboratory to listed company and is now established in some of the world's largest markets. The company markets NIOX MINO, a highly reliable and effective tool to assist in the diagnosis and control of airways disease.

Visit the site

Aerpio Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapeutics to treat disorders of the vasculature with an initial emphasis on diabetic macular edema.

Visit the site

Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. The Company's powerful research engine, based around three distinct antibody libraries and proprietary antibody formats, is driving the development of a strong, broad portfolio of antibodies that target cancer and other diseases. The unique properties of these libraries allows Affimed to identify antibodies against even the most difficult of targets. Affimed's proprietary antibody formats include 'TandAbs™', unique tetravalent antibodies that are particularly well suited to targeting tumor cells.

Visit the site

AIMS (Asian Institute of Medical Sciences) Hospital is a multi-specialty tertiary care hospital in North India with focus on oncology.

Visit the site

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector's strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets, an approach enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics.

Visit the site

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription.

Visit the site

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer.

With more than 500 distinct kinases identified and over 30 kinase inhibitors in clinical trials or FDA approved, this important class of proteins is a rich area for therapeutic drug development.

Ambit's lead compound AC220, a small molecule kinase inhibitor for the treatment of Acute Myeloid Leukemia, entered the clinic in 2006.

Visit the site

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has multiple drug candidates in late-stage clinical trial development.

Visit the site

arGEN-X is an innovation-driven biopharmaceutical company, transforming the discovery and development of human therapeutic antibodies. Its SIMPLE Antibody™ platform exploits outbred immune responses and gives universal, unbiased target epitope coverage, unravels new disease pathways and creates novel composition of matter intellectual property. This unique capability maximizes antibody lead choice - and together with proprietary half-life extension (NHance™) and enhanced cell killing (Potelligent®) technologies, has enabled arGEN-X to rapidly build an exciting preclinical pipeline of highly differentiated antibody therapeutics.

Visit the site

Focused on immuno-oncology

Visit the site

Arsanis is developing antibody therapeutics for infectious diseases for which current prophylactic or therapeutic approaches are ineffective or nonexistent. Arsanis has access to first-in-class human monoclonal antibody discovery technology that enables the selection of highly potent antibodies with unique biological properties.

Visit the site

Arteaus is a product-focused biotechnology company developing a novel treatment for migraine prevention. Arteaus is developing an antibody to calcitonin gene-related peptide (CGRP) as a novel approach for the prevention of migraine headaches. The world-wide rights to develop the antibody have been licensed from Eli Lilly and Company in an innovative collaboration that leverages Lilly's capabilities and experience developing the antibody with Arteaus' virtual and capital-efficient approach to achieving clinical proof of concept.

Visit the site

Developing gene therapy products for rare diseases

Visit the site

Avitide develops customized biopharmaceutical affinity purification products. The Avitide platform reduces bioprocess development timelines, program risk, and cost of manufacture by providing turnkey, cost-effective, highly specific affinity purification solutions. Industry-leading affinity resin discovery timelines integrate seamlessly into process development cycles, providing improved line-ofsight, platform operations and equipment, and predictable scalability.

Visit the site

Bacterin is a medical device company and accredited tissue bank that designs, processes, manufactures, and markets advanced medical products. Bacterin's Biologics Division, has revolutionized the handling characteristics of allograft bone while maintaining many of the benefits that are native functions of autograft bone. Bacterin's OsteoSponge® product line has a highly osteoconductive matrix that is essential for neovascularization and bone formation, while exhibiting osteoinductive properties by exposing native BMP's and growth factors. In addition to OsteoSponge®, Bacterin Biologics has an allograft portfolio designed specifically to meet the needs of the Spine, Cranio-maxillofacial, reconstructive, and trauma markets.

Visit the site

Since inception in 1971, BSV has worked ceaselessly to research, develop, manufacture and market specialized biological, pharmaceutical and biotechnology products. Today, BSV is one of the fast growing Indian bio-pharmaceutical companies. The product portfolio comprises of a wide range of products such as plasma derivatives, monoclonals, hormones, equine antitoxins and serums, antifungals, anaesthetics, cardiovascular and diagnostic products.

Visit the site

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel develops its product candidates by applying its proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.

Visit the site

Visit the site

Bonovo is a leading provider of orthopedic products to the Chinese healthcare market. Bonovo has over 15 years of experience manufacturing and distributing orthopedic products throughout China. Bonovo's unique relationships with leading clinicians and hospitals makes Bonovo an ideal partner for access to the Chinese orthopedic market.

Visit the site

Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary system for Transcatheter Mitral Valve Implantation (TMVI). Through the combination of a unique anchoring mechanism and a novel delivery catheter, physicians will be able to accurately and securely implant a new mitral valve within a beating heart, thus avoiding open-heart surgery. The CardiAQ procedure is designed to be performed in a cardiac catheterization laboratory or hybrid operating room. Ultimately, it will be similar to the Transcatheter Aortic Valve Implantation (TAVI) procedure, resulting in less trauma to the patient and substantial potential cost-savings to the healthcare system.

Visit the site

Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates.

Visit the site

cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.

cCAM has demonstrated proof of concept through in-vivo studies and is entering clinical studies. cCAM will select patients for its clinical studies based on  the fact that CEACAM1 can be measured on tumor cells. This selection may substantially reduce the risks associated with the studies and shorten the clinical path.

Visit the site

Cerapedics is developing and commercializing products for the orthopedic bone substitutes market. The Company's products utilize a proprietary small peptide called P-15™. This peptide has been identified to play an active role in initiating the formation of bone. Cerapedics' products should provide a safe, efficacious, and economical alternative to autograft and recombinant bone growth factor products for most procedures requiring a bone graft including spine fusion, trauma, and joint reconstruction.

Visit the site

Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on breakthrough research in HDL therapy, Cerenis is pursuing a range of HDL product candidates that reflect significant commercial opportunities in the treatment of atherosclerosis. High-density lipoprotein (HDL), also known as "good" cholesterol, is the primary vehicle for removal of excess cholesterol from the body through a process known as "reverse lipid transport." HDL is an important target area for new therapeutic agents to treat cardiovascular disease, which is the leading killer of men and women in industrialized nations

Visit the site

Cleave Biosciences is focused on novel targets in cellular protein homeostasis pathways. Controlled largely by two distinct systems - the ubiquitin proteasome system and the autophagy system, these pathways are utilized by cancer cells for their growth and survival.

Visit the site

Clementia is a privately-held, clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for people living with rare diseases by exploiting the use of novel retinoic acid receptor gamma agonists (RAR?) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva (FOP).



Visit the site

Crown Bioscience is a rapidly growing CRO with leadership in translational oncology and cancer drug discovery partnerships, expanding into diabetes and other disease areas with proprietary diabetic monkey models. Leveraging its unique translational oncology assets including HuPrime® and HuKemia® and full in-house drug discovery platforms, the company addresses the critical need of the pharmaceutical industry to improve R&D productivity while minimizing risks and retaining upside.

Visit the site

DFine's mission is to develop and market devices that treat vertebral compression fractures and other spinal disorders in a minimally invasive manner to improve patient quality of life.

DFine's RF Kyphoplasty procedure with the StabiliT® Vertebral Augmentation System is the next generation in kyphoplasty. It combines the benefits of site-specific cavity creation, controlled cement delivery, and potential for height restoration with ultra-high viscosity bone cement. During the procedure, radiofrequency energy is applied to specially formulated energy-responsive bone cement to create an ultra-high viscosity cement. The cement is delivered into a cavity within the vertebra using a remote hand switch that allows the physician to remain up to 10 feet from the fluoroscopic field, potentially reducing the physician's exposure to radiation.

Visit the site

Dimension Therapeutics is focused on advancing its gene therapy platform in rare diseases, beginning with lead programs in hemophilia A & B, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.

Visit the site

Domain Surgical develops and commercializes a thermal surgical energy platform based on ferromagnetic technology for precise cutting and coagulation of soft tissue. Domain Surgical's patented technology platform, the FMwand Ferromagnetic Surgical System, produces surface-only tissue effects without passing electrical energy through the patient, and is designed to provide unparalleled safety and predictability in the most critical surgical applications.

Visit the site

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 and DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Visit the site

EA is a medical device company focusing on R&D, manufacture and sales of orthodontics products in China. Since its inception, EA has set the bar for leadership in marketing and commercializing invisible orthodontic products. EA is the largest provider of invisible orthodontic products and services in China.

Visit the site

Ecron Acunova provides services for Phase I-IV clinical research, including clinical trial management, clinical data management, PK/PD services and central lab with its research centers in Europe and India. Ecron Acunova provides clinical development services to the pharmaceutical, biotechnology, nutritional, device and medical diagnostics industries. High service quality, wide therapeutic expertise and continuously expanding global reach are central to Ecron Acunova's long lasting commitment.

Visit the site

Eddingpharm is a leading pharmaceuticals marketing company in the fast growing China market. It focuses on in-licensing, marketing and distributing hospital pharmaceutical products.

With over 20 offices and 400 professional sales representatives, Eddingpharm is a partner of choice for many multi-national pharmaceutical companies.

Visit the site

GC Aesthetics is one of the largest independent aesthetic companies globally and is a leader in the aesthetic and plastic surgery market with their flagship brands: UK-based Nagor and France-based Eurosilicone. GC Aesthetics has more than 60 years of combined experience and excellence in implant development, manufacture and innovation and currently manufactures and sells breast implants in 90 countries, offering a wide product range with nearly 600 types of implants.

Visit the site

Glaukos Corporation is committed to transforming glaucoma therapy. To this end, Glaukos is bypassing anatomical impediments and treatment conventions to develop treatments that restore natural physiologic outflow as a foundation of significant, steady and sustained glaucoma management.

Visit the site

Good Start Genetics provides the most clinically relevant genetic information to physicians. The Company's affordable pre-pregnancy test utilizes an advanced DNA sequencing technology to screen for a panel of genetic disorders, including those recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG). Good Start Genetics' advanced DNA sequencing technology is designed to deliver a higher detection rate and improved clinical performance compared to currently available screening methods, such as genotyping and SNP analysis.

Visit the site

Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. Igenica contends that the key to next generation mAb-based medicines lies in both the identification of new targets and the deployment of novel antibody discovery approaches. To this end, the company has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective mAb drug candidates.

Visit the site

Inspire Medical Systems, Inc. has developed the world's first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient's unique breathing patterns.

Visit the site

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Visit the site

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of PBC in patients with an inadequate response to, or who are unable to tolerate, ursodiol (ursodeoxycholic acid), the only approved therapy for this indication. PBC is a chronic autoimmune liver disease that may progress to cirrhosis and liver failure, and it is currently the fifth leading indication for liver transplant in the United States. OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma.

Visit the site

Iroko is a global specialty pharmaceutical company dedicated to developing new drug products based on existing NSAIDs using innovative technology. Iroko's product pipeline consists of lower dose NSAIDs created using proprietary SoluMatrix Fine Particle Technology™. These drug products are designed to offer pain relief at lower doses.

Visit the site

Keystone Heart is focused on the development and commercialization of procedural tools and accessories for use during Transcatheter Aortic Valve Implantation (TAVI) and other complex percutaneous structural heart procedures. Keystone is finalizing the development of a novel embolic protection device to shield the brain from emboli during cardiac procedures. The Keystone Heart device is positioned at the aortic arch via a catheter in order to deflect emboli while allowing normal blood flow to the brain. The Keystone Heart device is designed to cover all three cerebral arterial branches off the aorta.

Visit the site

KIMS GCC is a chain of multi-specialty tertiary care hospitals and medical clinics with 100 beds under management focused on delivering high-quality medical care. The group currently manages a network of 6 healthcare delivery facilities in Bahrain, Oman, Saudi Arabia, Qatar and UAE.

Visit the site

KIMS India is a chain of multi-specialty tertiary care hospitals with 600 beds under management focused on delivering high-quality medical care. The group currently manages a network of 4 healthcare delivery facilities across India.

Visit the site

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery.

Visit the site

MacroGenics, Inc. is focused on the development of improved immunotherapeutic products, including monoclonal antibodies and vaccines and has identified new targets for the treatment of cancer and inflammatory disorders and the prevention of infectious diseases. The company has an important strategic partnership with Genzyme.

Visit the site

Medigus is a medical device company specializing in developing innovative endoscopic procedures and devices, including the revolutionary disposable endoscope for the treatment of GERD (Gastroesophageal Reflux Disease).

The company, which was founded in January 2000, is based in Israel and is publicly traded on the TASE. Medigus owns a unique and outstanding technological platform enabling the company to bring into the world state-of-the-art medical device products.

Visit the site

Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with a spectrum of complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using its proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates.

Visit the site

Natera is a leading genetic testing company that has developed a proprietary bioinformatics based technology (NATUS) to deliver accurate and comprehensive high-throughput testing for reproductive indications from tiny quantities of DNA. Natera operates a CLIA certified laboratory in San Carlos, California, providing a host of preconception and prenatal genetic testing services. Test offerings include pre implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paterni ty; carrier screening tests to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks.

Visit the site

NxStage Medical is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.

Visit the site

OmniGuide is committed to developing advanced energy surgical solutions that enhance precision, improve access and provide increased control in the field of minimally invasive surgery. Since its initial launch, the BeamPath® Laser System for minimally invasive surgery has been used in nearly 100,000 surgical procedures primarily in the fields of Gynecology and ENT. OmniGuide designs and manufactures its BeamPath Laser System in Cambridge, Massachusetts based on proprietary technology invented at MIT and originally published in Science and Nature. The Company couples its proprietary advanced energy delivery system with a line of flexible fiber-enabled CO₂ lasers for use in the operating room.

Visit the site

Ornim, Inc., through its fully owned subsidiary Ornim Medical Ltd., is bringing to market the CerOx™ monitor, both FDA-cleared and CE marked device that, using near infrared light and ultrasound waves, continuously, non-invasively and in tandem, monitors two critical parameters in adult patients: regional hemoglobin oxygen saturation in the brain or in regions of skeletal muscle tissue beneath the sensor and microcirculation blood flow in tissue. It is the only solution that offers measurement of this combination. Ornim anticipates that the combined measurement of oxygen saturation and blood flow will become essential during every medical procedure done under general anesthesia, for monitoring brain-injured patients, and during resuscitation. The CerOx monitor is designed for use in a variety of clinical settings including the operating room and the intensive care unit.

Visit the site

Otic Pharma Ltd is developing treatments for diseases of the ear. The company's treatments are based on foam, called "Foam-Otic", rather than drops. Foam-delivery is better than drops, because foams stay in place longer, improving the efficiency of the active pharmaceutical ingredient, such as an antibiotic or steroid, enabling lower and less frequent doses.

Visit the site

Otonomy is a clinical stage otology company with drug delivery technology enabling sustained release of drugs to the middle/inner ear. The company has two products in clinical trials, sustained release (SR) dexamethasone for Meniere's disease and SR ciprofloxacin for use at the time of tympanostomy tube surgery. The company has recently generated proof-of-concept data for both pipeline products.

Visit the site

OxOnc Development LP is an oncology development company founded by pharmaceutical development executives and oncology experts. OxOnc partners have extensive experience in building and managing oncology research networks in Europe and Asia and in managing global contract research organizations to optimally design and execute clinical trials.

Visit the site

PharmAbcine is a specialized biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases. Our mission is to develop a first-in-class and best-in-class mAb for those target diseases.

Visit the site

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Anticalins® are engineered binding proteins derived from the scaffold of natural human lipocalins. Anticalins are selected to have prescribed binding properties with selectivity and affinity fundamentally similar to that of monoclonal antibodies. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

Visit the site

Practice Fusion provides web-based electronic medical record systems. Its features include e-Prescribing, medical charting, scheduling, referral letters, lab integrations, patient management, patient health record, electronic medical record (EMR) integration and application programming interface (API), mobile EMR and support.

Visit the site

Principia is a privately held biopharmaceutical company focused on the design and development of reversible covalent small molecule drugs. The company is the dominant developer of reversible covalent therapeutics. Principia is creating a pipeline of differentiated drug candidates that offer superior safety and efficacy compared with other technologies. The company is leveraging its reversible covalent platform to build a pipeline of internal drug candidates and to establish partnerships with leading biopharmaceutical companies. Principia's platform is also being used to develop unique research tools to explore new biology, validate new disease targets, and serve as the source of its future pipeline.

Visit the site

ProNAi Therapeutics is applying proprietary, nucleic acid-based DNA interference technology to discover and develop novel therapeutic approaches for cancer and other diseases.

Visit the site

RDD Pharma is a drug-device company that developed an intra-anal drug delivery device that delivers a drug to the anal canal in a controlled manner.

The company utilizes a high-reward low-risk business model by repurposing drugs; By choosing medications that are already approved for other indications and combining them into our proprietary drug-delivery technology, RDD benefits from short regulatory route while maintaining our patent protection.

Visit the site

Realton Corporation is developing powerful and cost effective laser systems for use in the treatment of benign prostatic hyperplasia (BPH), a condition commonly known as enlarged prostate. Realton's surgical laser system and fiber optic delivery device are affordable to developing country hospitals and patients. Realton Corporation is headquartered and has manufacturing facilities in Beijing, and a subsidiary in Suzhou, China.

Visit the site

RedHill Biopharma is a biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer and related conditions.

Visit the site

Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non- absorbed potassium binder for the treatment of hyperkalemia. Relypsa is dedicated to the discovery of additional product candidates through use of its proprietary polymer platform.

Visit the site

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use.

Visit the site

Roka Bioscience is a privately held company focused on developing and commercializing innovative solutions based on molecular technologies for the industrial markets. The company's scientific platform is based on proven, proprietary technologies used widely in clinical diagnostic testing and now being introduced into food safety and other industrial markets. Roka's current product line provides food safety professionals with a fully automated molecular pathogen detection solution that delivers rapid, accurate results and improved laboratory efficiencies.

Visit the site

SAGE Therapeutics is a neuroscience-focused company developing medicines to treat rare and orphan diseases of the central nervous system (CNS). SAGE's lead program, SAGE-547, is in clinical development for super refractory status epilepticus and is the first of many compounds the company is developing in its portfolio of potential seizure medicines.  SAGE's robust allosteric modulator chemistry platform has generated multiple new compounds that target the GABAA and NMDA pathways, which have demonstrated preclinical activity.

Visit the site

Selecta is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. These synthetic vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information for highly-effective targeting to immune cells to produce an optimal immune response. Selecta's novel synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.

Visit the site

Shasun Pharmaceuticals Limited (Shasun), is a UK and India based contract research and manufacturing services company engaged in the manufacture and supply of Active Pharmaceutical Ingredients (API) and formulations to leading global pharmaceutical companies. The company has four API and formulation facilities, all of which are USFDA approved.

Visit the site

SI-BONE developed the iFuse Implant to System provide a less invasive alternative to traditional sacroiliac joint fusion surgery.  The iFuse Implant System is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis.

Visit the site

Sientra is a medical device company focused on developing and marketing a broad portfolio of products aimed at the fast growing plastic surgery and aesthetics market.

Visit the site

Singulex's technology has been developed into the Erenna™ Immunoassay System, which addresses unmet needs in biomarker discovery and validation. The Erenna System can detect as few as two hundred molecules, which meets or exceeds the detection limits of quantitative real-time PCR. Combining the Erenna System's nanotechnology with tried and proven high-throughput immunoassay micro-technology, Singulex has developed protein assays that are 100-1,000 times more sensitive and use 20-100 fold less sample. This enables detailed industrial-scale analysis of precious clinical specimen repositories, cell culture preparations, and other biological specimens that otherwise cannot be studied.

Visit the site

 Founded in 2006 as Dentatek Corporation by life science-focused accelerator Fjord Ventures, LLC, Sonendo is a privately-held pre-revenue stage company developing innovative technologies to transform endodontic therapy. Sonendo has a new disruptive technology that promises to transform the way root canal therapy (endodontics) is performed. As opposed to current endodontic files that only touch 30-70% of the canal surface, Sonendo's Multisonic Ultracleaning™ technology reaches and cleans everywhere within the canal. In-vitro and in-vivo clinical studies show that Sonendo cleans faster, easier, and better than current available endodontic materials and devices.

Visit the site

Surya Children's Medicare Private Limited is a chain of specialty hospitals in Western India focusing on neonatal and pediatric care. In addition, the company also provides high-risk maternity care services.

Visit the site

Symbiomix is a late-stage, privately held biopharmaceutical company with a focus on women's health. The company's lead product, SYM-1219, is a new anti-infective drug being studied as the first oral one-and-done treatment in the United States for bacterial vaginosis (BV), a common but underappreciated gynecological infection that greatly increases the risk of serious health problems.

Visit the site

Developing novel biologic mesh implant products

Visit the site

Used in over 3,000 facilities, TigerText has established itself as the leader in secure messaging for healthcare. From large hospital networks to small private practices, healthcare organizations use TigerText as their preferred method of secure communication to comply with HIPAA, HITECH and other industry standards.

Visit the site

Treato Ltd. provides social health patient intelligence solutions. Its patient intelligence platform offers both patients and healthcare stakeholders unique insights based on the aggregated wisdom of the crowd through its free patient site, treato.com, and its professional service offering, Treato Pharma.

Visit the site

Unilife is a developer and commercial supplier of injectable drug delivery systems whose broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Unilife builds long-term collaborations with pharmaceutical and biotechnology companies seeking to utilize Unilife's products by providing innovative, differentiated, and customizable solutions.

Visit the site

ViewRay's technology, the Renaissance™ System 1000, promises to be the world's first radiation therapy device to allow real-time MRI simultaneous with beam-on radiation delivery. This will enable the healthcare professional to know and do what was previously impossible: to understand where the dose actually went in the patient on any given on-couch radiation therapy session, and to gate the beam in real-time based on the actual anatomy of the patient.

Visit the site

Waterstone Pharmaceuticals, a fully-integrated specialty pharmaceutical company, is specialized in developing, manufacturing and marketing pharmaceutical intermediates, APIs and formulations at global standards.

Visit the site

Whale Imaging focuses on the R&D, manufacturing, and marketing of high-tech medical imaging devices which utilizes the company's unique core competencies that combine lowest cost manufacture with high level management experience. We combine low-cost R&D and manufacturing with a highly-skilled and experienced management and workforce to produce high quality and optimal value for our customers, above average returns for our stakeholders, and opportunity for our employees.

Our aim is to be the leader in producing affordable world-class medical imaging systems to our global customers by leveraging our proven proprietary disruptive technology, management expertise, and low-cost manufacturing capabilities in China.

Visit the site